How does antibody-drug conjugate (ADC) therapy work for Ovarian Cancer

How Antibody-Drug Conjugate (ADC) Therapy Works for Ovarian Cancer

The Basic Mechanism: A Targeted Delivery System

An ADC is essentially a precision delivery vehicle. Think of it as a guided missile designed to find cancer cells and deliver a toxic payload directly to them. Here's how it works:

The Three Components:

1. The Antibody - A targeting protein that recognizes and binds to a specific marker (antigen) on cancer cell surfaces
2. The Linker - A chemical connector that holds the antibody and drug together
3. The Payload - A toxic drug attached to the antibody that kills the cancer cell once delivered

According to the CancerPatientLab webinar on "Clinical Guidance from Proteomics," when an ADC binds to its target on a cancer cell, the cell internalizes (pulls in) the entire complex. Once inside, the toxic payload is released and attacks the cancer cell's critical functions—often targeting tubulin (a protein needed for cell division) or TOPO1 (an enzyme required for DNA replication).

---

Why ADCs Matter for Ovarian Cancer

The Advantage Over Traditional Chemotherapy: Traditional chemotherapy circulates throughout your entire body, damaging both cancer cells AND healthy cells. ADCs are more selective—they primarily target cancer cells that express the specific marker the antibody recognizes, potentially reducing side effects to normal tissues.

Bystander Activity: Some newer ADCs have an additional benefit called "bystander activity." This means the toxic payload can leak out of the cancer cell and kill neighboring cancer cells as well, even if those neighboring cells don't have the target marker. This can increase effectiveness.

---

Key Targets in Ovarian Cancer

For ovarian cancer specifically, several targets are being explored:

TROP2 (Trophoblast Cell-Surface Antigen-2)

According to the proteomics guidance, TROP2 is expressed in many cancer types. When TROP2 is targeted with a TOPO1 inhibitor payload (like in the Gilead drug sacituzumab govitecan), the combination can shrink tumors by attacking the cancer cell's ability to replicate DNA.

HER2 (Human Epidermal Growth Factor Receptor 2)

While HER2 is most famous in breast cancer, it's also relevant in some ovarian cancers. The webinar discusses how HER2 expression levels matter—patients with "HER2 low" tumors may benefit from newer ADCs like trastuzumab deruxtecan (Enhertu), which combines anti-HER2 targeting with a TOPO1 inhibitor.

Other Emerging Targets

Research is exploring additional targets like B7-H3 and NECTIN4 in ovarian cancer, with multiple ADCs in clinical development.

---

How Doctors Decide If ADCs Will Work for Your Case

Three Possible Scenarios (based on the clinical guidance):

1. The receptor isn't present → The ADC cannot bind, so it won't be effective
2. The ADC binds but resistance mechanisms block it → The cancer cell has built-in defenses (like tubulin beta-3 mutations) that prevent the toxic payload from working
3. The ADC binds and no resistance exists → The therapy should work effectively

This is why knowing your tumor's specific biomarker profile (protein expression levels) can be valuable—it helps predict which ADCs are most likely to be effective for YOUR cancer.

---

Current ADC Options for Ovarian Cancer

According to NCCN Guidelines and recent clinical data, ADCs are increasingly being incorporated into ovarian cancer treatment, particularly for:

• Platinum-resistant ovarian cancer (cancer that returns quickly after platinum-based chemotherapy)
• Recurrent ovarian cancer with specific biomarker profiles
• Combination approaches with other therapies like immunotherapy or PARP inhibitors

---

Questions to Ask Your Oncology Team

1. Has my tumor been tested for TROP2, HER2, or other ADC targets? If not, would that testing be helpful for my treatment planning?

2. Are there any ADC-based clinical trials I might be eligible for based on my tumor's biomarker profile?

3. If an ADC is recommended, which specific target and payload combination do you think is best for my cancer, and why?

4. How would an ADC fit into my overall treatment plan? (For example, would it be used alone, combined with chemotherapy, or combined with immunotherapy?)

5. What side effects should I expect, and how do they compare to my other treatment options?

---

Important Context

ADC therapy represents an exciting advancement in precision oncology—moving away from "one-size-fits-all" chemotherapy toward treatments tailored to your specific tumor's characteristics. However, the field is still evolving, and not all ADCs are yet FDA-approved for ovarian cancer specifically. Your oncologist will determine which approaches are appropriate for YOUR individual case based on your tumor's stage, biomarker profile, prior treatments, and overall health.

According to the CancerPatientLab webinars on proteomics and personalized treatment, knowing your tumor's protein expression levels can help "stack the odds in your favor" by identifying which targeted therapies are most likely to work for you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.